CARES

Cabotegravir And Rilpivirine: Efficacy and Safety Study

About CARES

HIV treatment, now commonly known as Antiretroviral therapy (ART) has been in use since the first drug Zidovine (AZT) was discovered in 1987. Subsequent developments have aimed at maximising the benefits of the treatment while also minimising side effects and increasing tolerability through simplification.

The CARES study, the first of its kind in Africa sets out to determine if the use of Long-acting injectable ART is feasible, safe and efficacious in a public health set up in Africa. With funding from Janssen EMEA and drug donations from both manufactures of Cabotegravir ((Viiv/GSK) and Rilpivirine (Janssen), a multi national clinical trial, coordinated by the Joint C clinical Research Centre has been set up. The overall aim of this study is to determine/demonstrate that switching from taking daily ART pills to injectable long acting RPV +CAB will not reduce the effectiveness of the ART on the participants.

home_about

Our highly skilled team of researchers ad support personnel has helped us to succeed in areas where others have failed.

We’ve revolutionised the way businesses are started

We believe in the power of business startup to change lives and change the world

Working globally with enterprise partners

We are connecting Investors, Service providers, Industry leaders with Startups ready to rise

and show themselves to the world.

We know exactly all the milestones and criteria which are important for investors.
We know exactly all the milestones and criteria which are important for investors.
We know exactly all the milestones and criteria which are important for investors.
Contact us today! We’d love to hear from you!

Need our help?
Contact us to get FREE consultation!